Skip to main content
Figure 1 | BMC Pulmonary Medicine

Figure 1

From: Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study

Figure 1

Hemodynamic and symptomatic changes before and after the dual PDE5i therapy. a. Effect of PDE5i dual therapy on mPAP. The red line indicates mean change of mPAP (± SD) from 47.9 ± 9.7 mmHg to 41.7 ± 9.2 mmHg. b. Effect of PDE5i dual therapy on PVR. The red line indicates mean change of PVR (± SD) from 9.3 ± 2.7 Wood’s Units to 6.7 ± 2.9 Wood’s Units. c. Effect of PDE5i dual therapy on CI. The red line indicates mean change of CI (± SD) from 2.8 ± 0.9 L/min/m2 to 3.1 ± 0.8 L/min/m2. d. Effect of PDE5i dual therapy on 6MWTD. The red line indicates mean change of 6MWD (± SD) from 353 ± 60 m to 382 ± 62 m. e. Effect of PDE5i dual therapy on NYHA functional class. mPAP: mean pulmonary artery pressure, PVR: pulmonary vascular resistance, WU: Wood’s units, CI: cardiac index, 6MWD: six minutes walk distance.

Back to article page